Cooley Wins Multiple LMG Life Sciences EMEA Awards
London – May 20, 2024 – Cooley’s life sciences practice received multiple LMG Life Sciences EMEA (Europe, the Middle East and Africa) Awards at a ceremony in London on May 16. Firmwide, the team was recognized as Venture Capital Firm of the Year, while associate Mark Jones was honored individually as a Financial Rising Star.
The firm’s work on behalf of clients was noted in four Impact Deals of the Year, as based on representations of:
- Amryt Pharma, a commercial-stage biopharmaceutical company, in its $1.48 billion sale to Chiesi Farmaceutici.
- Ascend Gene & Cell Therapies, a gene therapy technology company, in its $130 million Series A financing.
- Bavarian Nordic, a vaccine company, in its $380 million acquisition of Emergent BioSolutions’ travel vaccines portfolio.
- VectivBio, a clinical-stage biotech company focused on treating rare gastrointestinal conditions, on its $1 billion sale to Ironwood.
The firm also was shortlisted for recognition as Corporate Firm of the Year, Licensing & Collaboration Firm of the Year, M&A Firm of the Year, Patent Litigation Firm of the Year: Biotech and Regulatory Firm of the Year.
LMG Life Sciences produces one of the most respected awards programs for life sciences practitioners and firms in the US, Canada, Europe, the Middle East and Africa. Winners are determined through a rigorous research process that aims to survey excellent legal service over a 12-month period. Covered in the award categories are four key practice areas – financial and corporate, regulatory, intellectual property (IP), and non-IP litigation and enforcement.
Cooley is a top law firm for emerging and mature life sciences companies, nearly 2,500 public and private life sciences clients worldwide, including almost 50% of the Nasdaq Biotechnology Index. Clients include innovative biotech and specialty pharmaceutical companies at the forefront of new technologies, including cell and gene therapies, artificial intelligence-led drug discovery and new vaccine technologies. Cooley was recently named Law360’s Life Sciences Practice Group of the Year and has been the #1 venture capital law firm for biotech and pharma venture financings for the last decade (PitchBook). Cooley also is the #1 firm for issuer-side life sciences IPOs (Deal Point Data) – a title held since 2000. LMG Life Sciences previously named Cooley Corporate Firm of the Year and M&A Firm of the Year in 2023, and Licensing & Collaboration Firm of the Year in 2022.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.